Date: 
, Time: , Headline: Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
Date: 
, Time: , Headline: Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Date: 
, Time: , Headline: Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA  Technology
Date: 
, Time: , Headline: Biotech stock tumbles after unexplained 1,446% gain
Date: 
, Time: , Headline: Bright Minds is Unaware of Any Material Changes
Date: 
, Time: , Headline: Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Date: 
, Time: , Headline: Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Date: 
, Time: , Headline: Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Date: 
, Time: , Headline: Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Date: 
, Time: , Headline: DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
Date: 
, Time: , Headline: Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Date: 
, Time: , Headline: Bright Minds Announces Effective Date of Share Consolidation
Date: 
, Time: , Headline: Bright Minds Announces Proposed Share Consolidation
Date: 
, Time: , Headline: Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Date: 
, Time: , Headline: Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Date: 
, Time: , Headline: Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Non-Executive Director Appointment
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Resignation of Board Member
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Non-Brokered Private Placement
Date: 
, Time: , Headline: Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
Date: 
, Time: , Headline: Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
Date: 
, Time: , Headline: Bright Minds Announces Pricing of Overnight Marketed Offering of Units
Date: 
, Time: , Headline: Bright Minds Announces Overnight Marketed Offering of Units
Date: 
, Time: , Headline: Bright Minds Biosciences Comments on Recent Trading Activity
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
Date: 
, Time: , Headline: Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
Date: 
, Time: , Headline: Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
Date: 
, Time: , Headline: Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
Date: 
, Time: , Headline: Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Date: 
, Time: , Headline: Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
Date: 
, Time: , Headline: Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
Date: 
, Time: , Headline: Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone
Date: 
, Time: , Headline: Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
Date: 
, Time: , Headline: Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
